[go: up one dir, main page]

DE69431404D1 - Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe - Google Patents

Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe

Info

Publication number
DE69431404D1
DE69431404D1 DE69431404T DE69431404T DE69431404D1 DE 69431404 D1 DE69431404 D1 DE 69431404D1 DE 69431404 T DE69431404 T DE 69431404T DE 69431404 T DE69431404 T DE 69431404T DE 69431404 D1 DE69431404 D1 DE 69431404D1
Authority
DE
Germany
Prior art keywords
compositions
vaccine
micro
encoding antigens
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69431404T
Other languages
English (en)
Other versions
DE69431404T2 (de
Inventor
L Cleland
Amy Lim
Frank Powell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE69431404D1 publication Critical patent/DE69431404D1/de
Application granted granted Critical
Publication of DE69431404T2 publication Critical patent/DE69431404T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
DE69431404T 1993-10-22 1994-10-13 Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe Expired - Lifetime DE69431404T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14179693A 1993-10-22 1993-10-22
US14355593A 1993-10-25 1993-10-25
PCT/US1994/011753 WO1995011010A1 (en) 1993-10-22 1994-10-13 Methods and compositions for microencapsulation of antigens for use as vaccines

Publications (2)

Publication Number Publication Date
DE69431404D1 true DE69431404D1 (de) 2002-10-24
DE69431404T2 DE69431404T2 (de) 2003-04-30

Family

ID=26839455

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69431404T Expired - Lifetime DE69431404T2 (de) 1993-10-22 1994-10-13 Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe

Country Status (9)

Country Link
EP (1) EP0724432B1 (de)
JP (1) JPH09504027A (de)
AT (1) ATE224184T1 (de)
AU (1) AU7980794A (de)
CA (1) CA2172509C (de)
DE (1) DE69431404T2 (de)
DK (1) DK0724432T3 (de)
ES (1) ES2184769T3 (de)
WO (1) WO1995011010A1 (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40786E1 (en) * 1984-03-16 2009-06-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US6514533B1 (en) 1992-06-11 2003-02-04 Alkermas Controlled Therapeutics, Inc. Device for the sustained release of aggregation-stabilized, biologically active agent
WO1994019020A1 (en) * 1993-02-23 1994-09-01 Genentech, Inc. Excipient stabilization of polypeptides treated with organic solvents
DK0724433T3 (da) * 1993-10-22 1999-08-30 Genentech Inc Fremgangsmåde til fremstilling af mikrosfærer med et tørringstrin i fluidiseret leje
GB9514285D0 (en) * 1995-07-13 1995-09-13 Univ Nottingham Polymeric lamellar substrate particles for drug delivery
GB2317340B (en) * 1995-07-13 1998-12-23 Danbiosyst Uk Polymeric lamellar substrate particles for drug delivery
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
AU710347B2 (en) * 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
GB9709900D0 (en) * 1997-05-15 1997-07-09 Microbiological Res Authority Microencapsulated DNA for vaccination and gene therapy
US6312731B1 (en) * 1997-08-29 2001-11-06 Southern Research Institute Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
EP1579851A3 (de) * 1997-08-29 2009-09-02 Corixa Corporation Schnellfreisetzende enkapsulierte bioaktive Wirkstoffe zur Induzierung oder Erhöhung einer immunantwort und Verwendung derselben
CA2314934C (en) * 1997-12-16 2006-08-29 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
US7393630B2 (en) 1997-12-16 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Use of microparticles combined with submicron oil-in-water emulsions
SE9801288D0 (sv) 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
WO2001058466A1 (en) * 2000-02-08 2001-08-16 Institute Of Molecular Agrobiology Biodegradable and biocompatible polymeric microspheres encapsulating salmonella enteritidisbacteria
ES2160089B1 (es) * 2000-03-15 2002-05-16 Inst Cientifico Tecnol Navarra Procedimiento y aparato para la produccion de microparticulas para la liberacion controlada de farmacos hidrosolubles y vectores virales. aplicacion a la adiministracion de adn plasmidico y de adenovirus recombinantes defectivos.
US6565888B1 (en) 2000-08-23 2003-05-20 Alkermes Controlled Therapeutics, Inc. Methods and compositions for the targeted delivery of biologically active agents
AU2002354644C1 (en) * 2001-07-10 2009-04-30 Corixa Corporation Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
EP1556019A2 (de) 2002-10-24 2005-07-27 Merz Pharma GmbH & Co. KGaA Kombinationstherapie unter verwendung von 1-aminocyclohexan derivaten und acetylcholinesterase inhibitoren
KR20070104480A (ko) 2003-05-27 2007-10-25 포레스트 래보러토리즈, 인코포레이티드 우울증 및 그 밖의 기분장애의 치료를 위한 ｎｍｄａ수용체 길항제 및 선택적 세로토닌 재흡수 억제제의 배합물
EP1720565A1 (de) * 2004-03-04 2006-11-15 Corixa Corporation Co-verkapselte wt1-polypeptid und immunstimulierende mikrokügelchen-formulierungen und verfahren dafür
CN100342916C (zh) * 2004-12-08 2007-10-17 上海第二医科大学附属第九人民医院 一种可生物降解医用材料标记物及其制备
US8088382B2 (en) 2005-07-05 2012-01-03 Cornell Research Foundation, Inc. Methods of inhibiting transendothelial migration of neutrophils and monocytes with anti-CD99L2 antibodies
EP1932538A4 (de) 2005-08-25 2009-10-21 Taiho Pharmaceutical Co Ltd Biologisch abbaubare nanoteilchen mit darauf immobilisiertem oder darin verkapseltem t-zell-erkennbarem epitop-peptid
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
AR071728A1 (es) 2007-09-12 2010-07-14 Merz Pharma Gmbh & Co Kgaa Terapia con intervalos para el tratamiento del tinnitus
ES2358703B1 (es) * 2007-11-14 2012-03-21 Universidad Del Pais Vasco Empleo de micropart�?culas para su uso como vacunas y la liberación de moléculas biológicamente activas.
ES2327375B1 (es) 2007-11-14 2010-08-05 Universidad Del Pais Vasco Empleo de microparticulas para su uso como vacunas y la liberacion de moleculas biologicamente activas.
EP2085120A1 (de) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Verwendung von Substanzen zur Behandlung zentraler und peripherer Insulinrezeptorbeeinträchtigung oder Insulinresistenz
DK2318832T3 (da) 2008-07-15 2014-01-20 Academia Sinica Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
TWI432188B (zh) 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類
CA2737335C (en) 2008-12-19 2013-10-01 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
WO2011000564A1 (en) 2009-06-30 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of drug addiction
EP2448579A1 (de) 2009-06-30 2012-05-09 Merz Pharma GmbH & Co. KGaA Eltoprazin zur behandlung von gewichtsstörungen
WO2011000565A1 (en) 2009-06-30 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of anxiety
WO2011000562A1 (en) 2009-06-30 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of certain movement disorders
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
US20110294890A1 (en) 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
WO2012023033A2 (en) 2010-08-18 2012-02-23 Purdue Pharma L.P. Improved peptide immunogens
JP6084931B2 (ja) 2011-01-20 2017-02-22 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン ストレス又は急性聴力損失に関連する耳鳴の治療又は予防のためのネラメキサン
WO2012171653A1 (en) 2011-06-15 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Sarizotan for use in the treatment of attention deficit hyperactivity disorder (adhd)
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
TW201412325A (zh) 2012-06-20 2014-04-01 梅茲製藥有限兩合公司 用於治療患有青光眼及其他退化性眼疾之人類視力喪失的間隔醫療
JP6302909B2 (ja) 2012-08-18 2018-03-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ シアリダーゼの同定および画像化のための細胞透過性プローブ
HK1208623A1 (en) * 2012-11-09 2016-03-11 赢创有限公司 Drying methods for tuning microparticle properties
WO2014210397A1 (en) 2013-06-26 2014-12-31 Academia Sinica Rm2 antigens and use thereof
EP3013347B1 (de) 2013-06-27 2019-12-11 Academia Sinica Glykankonjugate und verwendung davon
CA2923579C (en) 2013-09-06 2023-09-05 Academia Sinica Human inkt cell activation using glycolipids with altered glycosyl groups
CN105764921B (zh) 2013-09-17 2020-06-30 台湾浩鼎生技股份有限公司 用于诱导免疫反应的糖疫苗组合物及其治疗癌症的用途
CA2933867A1 (en) * 2013-12-16 2015-06-25 Massachusetts Institute Of Technology Micromolded or 3-d printed pulsatile release vaccine formulations
CN106061292B (zh) 2013-12-16 2020-01-21 麻省理工学院 强化的微量营养素盐调配物
JP2017507118A (ja) 2014-01-16 2017-03-16 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ がんの処置および検出のための組成物および方法
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
CN106415244B (zh) 2014-03-27 2020-04-24 中央研究院 反应性标记化合物及其用途
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR20170003720A (ko) 2014-05-27 2017-01-09 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
WO2015184008A1 (en) 2014-05-27 2015-12-03 Academia Sinica Fucosidase from bacteroides and methods using the same
CA2950440A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-her2 glycoantibodies and uses thereof
CN106714829A (zh) 2014-05-28 2017-05-24 中央研究院 抗TNF‑α醣抗体及其用途
US9439864B2 (en) * 2014-07-07 2016-09-13 Antriabio, Inc. Solvent extraction from biodegradable microparticles
EP3191500A4 (de) 2014-09-08 2018-04-11 Academia Sinica Aktivierung menschlicher inkt-zellen mithilfe von glykolipiden
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
EP3248005B1 (de) 2015-01-24 2020-12-09 Academia Sinica Neuartige glycankonjugate und verfahren zur verwendung davon
HK1256912A1 (zh) 2015-09-04 2019-10-04 台湾浩鼎生技股份有限公司 聚糖阵列以及使用方法
CN109195996A (zh) 2016-03-08 2019-01-11 中央研究院 N-聚醣及其阵列的模组化合成方法
CN109311995A (zh) 2016-03-29 2019-02-05 台湾浩鼎生技股份有限公司 抗体、药物组合物和方法
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
RU2018140976A (ru) 2016-04-22 2020-05-22 Оби Фарма, Инк. Иммунотерапия рака путем иммунной активации или иммунной модуляции через антигены серии globo
CN115537372A (zh) 2016-07-13 2022-12-30 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
KR20230117482A (ko) 2016-07-27 2023-08-08 오비아이 파머 인코퍼레이티드 면역원성/치료 글리칸 조성물 및 그의 용도
KR102528998B1 (ko) 2016-07-29 2023-05-03 오비아이 파머 인코퍼레이티드 인간 항체, 제약 조성물 및 방법
CN109963868B (zh) 2016-08-22 2023-11-14 醣基生医股份有限公司 抗体、结合片段及使用方法
CN110290800A (zh) 2016-11-21 2019-09-27 台湾浩鼎生技股份有限公司 缀合生物分子、医药组合物及方法
WO2020006176A1 (en) 2018-06-27 2020-01-02 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
EP3791873A1 (de) 2019-09-16 2021-03-17 Universite De Bordeaux Verfahren zur behandlung und/oder vorbeugung von erkrankungen und symptomen im zusammenhang mit bkca- und/oder sk-kanalophathien
US12390537B2 (en) 2020-05-13 2025-08-19 Massachusetts Institute Of Technology Compositions of polymeric microdevices and methods of use thereof in cancer immunotherapy
US11992559B2 (en) 2021-02-24 2024-05-28 Oakwood Laboratories, Llc Microsphere formulations comprising lurasidone and methods for making and using the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
ATE151638T1 (de) * 1987-02-20 1997-05-15 Genentech Inc Verfahren und zubereitungen für die verwendung von hiv-env-polypeptiden und antikörpern
US5008116A (en) * 1988-11-14 1991-04-16 Frederick Cahn Immunostimulatory microsphere
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル

Also Published As

Publication number Publication date
ES2184769T3 (es) 2003-04-16
DK0724432T3 (da) 2003-01-27
WO1995011010A1 (en) 1995-04-27
AU7980794A (en) 1995-05-08
JPH09504027A (ja) 1997-04-22
EP0724432B1 (de) 2002-09-18
ATE224184T1 (de) 2002-10-15
CA2172509C (en) 2010-08-24
CA2172509A1 (en) 1995-04-27
DE69431404T2 (de) 2003-04-30
EP0724432A1 (de) 1996-08-07

Similar Documents

Publication Publication Date Title
DE69431404D1 (de) Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe
DE69431358D1 (de) Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien
ES2181674T3 (es) Dominios de union en las proteinas notch y delta.
DE3768833D1 (de) Verfahren zur herstellung von hcmv-glykoproteinen, antikoerper dagegen und hcmv-vakzine und dazu zu verwendende rekombinante vektoren.
ATE466869T1 (de) Verfahren zur herstellung von immunogenen hla- a2.1-bindenden peptiden
ATE391783T1 (de) Verfahren und reagenzien zur erzeugung einer cd8+ t-zellen immunantwort gegen melanoma
ATE295895T1 (de) Genetischer impfstoff gegen den immunschwäche virus
ATE269100T1 (de) Verfahren zur therapeutischen impfung
DK0851927T3 (da) Forbindelser til immunterapi og diagnosticering af tuberkulose
DK0585943T3 (da) Opløselige ligander for CD40
BR9809656A (pt) Composição imunopotencializante
DE69231837T8 (de) Antigen praesentierende ms2-huelle
DK1042001T3 (da) Anvendelse af mikropartikler kombineret med submikron-(olie-i-vand)-emulsioner
DE60004496D1 (de) Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff
DE69930753D1 (de) Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff-zusammensetzungen dazu
ATE424217T1 (de) Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
ATE72400T1 (de) Kreuzreaktive und schuetzende epitope von circumsporozoit-proteinen.
DE69922804D1 (de) Verwendung von polymeren der hyaluronsäure zur mukosalen freigabe von impfstoffen und adjuvantien
DE3787121D1 (de) Verfahren zur Herstellung und Verwendung von Katzenleukämievirus-Antigenen.
DE69429521D1 (de) Zusammensetzung und verfahren zur stimulation der reproduzierenden leistung
DE3884672D1 (de) Ein synthetisches Nonapeptid zur Verwendung als Adjuvant.
ATE152916T1 (de) Die verwendung von anti-helminth impfstoffen zur kontrolle von parasitären krankheiten, die mit einem verlust der natürlichen immunität assoziiert sind
DK0542895T3 (da) Krydsreaktiv influenza A immunisering
DE60034460D1 (de) Verwendung von trehalose produzierenden prokaryotischen zellen als impfstoffe
ATE65028T1 (de) Verfahren zur herstellung der bordetellapertussis-schutzantigene enthaltenden ha fraktion und keuchhustenvakzin.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition